The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.

For questions, call (404)-255-1930

For the Sixth Consecutive Year, NSH-BMT's One Year Related and Unrelated Allogeneic Transplant Survival Outcomes Were Among the Best in the U.S.1,2

1. Reported outcome data from This survival information includes only patients who received their first allogeneic transplant between January 1, 2010 and December 31, 2012 using unrelated or related donors, and who had reported follow-up.
2. Final 2014 Transplant Center Specific Survival Report, November 24, 2014.

Please go to Survival for additional NSH-BMT survival outcome data information.

NSH- Leukemia Program Featured in the August 2015 Issue of Atlanta Medicine Magazine

NSH- Leukemia Program’s Medical Director, Dr. Lawrence Morris, was published in the August issue of Atlanta Medicine Magazine, a journal of the Medical Association of Atlanta. His article, ‘Leukemia Program Finds Success with Patient Centered Care’, describes how NSH- Leukemia Program offers the leukemia patient with immediate access to an experienced team of physicians, support staff equipped to efficiently navigate them through the continuum of care and access to state-of-the-art clinical research trials from the NCI, pharmaceutical companies and collaborations with other academic university leukemia programs.

To read the Atlanta Medicine Magazine NSH-Leukemia Program article click here.

NSH- BMT/Leukemia Program Presents at the Atlanta, GA
MDS Foundation’s Patient and Family Forum

On August 15, 2015, NSH-BMT/Leukemia physician, Dr. Solh and the NSH - Leukemia Program coordinators, spoke at the Atlanta MDS Foundation’s Patient and Family Forum held at the Hyatt Villa Christina Hotel. Over fifty patients and family members joined the MDS Foundation and NSH-BMT/Leukemia program in this patient educational meeting. Topics discussed included; new clinical research trials, disease education and support organizations. NSH - Leukemia Program coordinators reviewed and discussed the MDS Foundation’s ‘Building Blocks of Hope’, which can be found on the MDS Foundation’s website,, and the BMTGA website,

For additional MDS Foundation resources and support, please call 1-800-MDS-0839, e-mail, or write, The MDS Foundation 4573 South Broad St., Suite 150 Yardville, NJ 08620.

NSH-BMT’s CIBMTR Scientific Working Committee Leadership Recognition

After the 2014-2015 review of the CIBMTR’s Scientific Working Committees, four have been recognized as outstanding by the Advisory Committee:

  • Chronic Leukemia
  • Graft Sources and Manipulation – NSH-BMT’s Asad Bashey, PhD, Chair
  • Late Effects and Quality of Life
  • Lymphoma

These committees were identified because of their strong promotion of studies that will have a notable impact on the field, willingness to forgo studies that will not have a significant impact on the field, and focus on the effective use of CIBMTR resources. In addition, these committees have cultivated external collaborations and are notably well-organized and highly productive.

For a full list of CIBMTR Scientific Working Committee leadership recognition, please review here.

Dr. Melhem Solh Joins BMTGA and the NSH-BMT and Leukemia Programs

We are pleased to announce Dr. Melhem Solh has joined BMTGA and NSH-BMT/Leukemia programs. Prior to joining our Team, Dr. Solh was the Clinical Director for the Florida Center for Cellular Therapy Bone Marrow Transplant Program, Medical Director for the Cellular Therapy Laboratory and an Assistant Professor of Medicine at the University of Central Florida. Dr. Solh is a board certified hematologist and oncologist. At the University of Minnesota, Dr Solh completed a hematology, oncology and blood and marrow transplant fellowship training program.

Dr. Solh has authored and co-authored over 40 abstracts and publications in peer reviewed journals: Biology of Blood and Marrow Transplant, Bone Marrow Transplantation, American Journal of Hematology. Dr. Sohl’s clinical research interests include the development of innovative therapies for leukemia and malignant blood disorders.

Dr. Solh is seeing new patients and can be reached at 404-255-1930.

NSH- BMT/Leukemia Patient Craig Sager’s Message of Hope

TNT's Inside the NBA Interview

NSH-BMT Program Named as Core Clinical Transplant Center

NSH-BMT is the only transplant program in Georgia to receive the prestigious designation of Core Clinical Center from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN). This designation is accompanied by a research grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The Program is one of 20 out of more than 120 such BMT Programs in the United States to be awarded this status.


NSH-BMT/Leukemia Programs will Present Three Oral and Five Poster Presentations at the 2014 American Society of Hematology: ASH Meeting

The NSH-BMT/Leukemia Programs have been recognized by ASH for their innovative and state-of- the-art clinical research efforts in blood and marrow transplantation and leukemia therapies. Having three oral and five post presentations selected for presentation, represents the commitment NSH-BMT/Leukemia Programs have towards their patients by providing them with the best and most cutting edge treatments for blood, marrow and leukemia diseases.

The presentations will include the following:

  • TBI-Based Myeloablative Haploidentical Stem Cell Transplantation is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors. ORAL ABSTRACT #426
  • The Psychosocial Transplant Evaluation Rating Scale (TERS) Prospectively Predicts Inferior Overall Survival Outcome for High Risk Scoring Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. ORAL ABSTRACT # 207
  • Survival after T-Replete Haplo-identical Related Donor Transplants Using Post-Transplant Cyclophosphamide Compared with Match Unrelated Donor Transplantation for Acute Myeloid Leukemia: An Analysis from the CIBMTR. ORAL ABSTRACT # 679
  • Five Posters by the NSH-BMT/Leukemia clinical pharmacists and BMT physician team members.
Please review Publications to review NSH - BMT's contributions in advancing the field of blood and marrow transplant/leukemia therapies.

NSH-BMT/Leukemia Programs Publish in Peer Reviewed Journals to Advance the Field of Blood, Marrow and Leukemia Therapies

In 2014, NSH-BMT/Leukemia physicians and team had the following peer reviewed articles published:

Real-Life Experience of a Brief Arsenic Trioxide (ATO)-based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia (APL): Favorable Outcomes with Limited Anthracycline Exposure and Shorter Consolidation Therapy, Mindy Leech, PharmD; Lawrence Morris; Moishe Stewart; Douglas Smith; Asad Bashey; Kent Holland; Scott Solomon; Xu Zhang; Hetty E Carraway; Keith Pratz; Steven Gore; Amer M Zeidan. Clinical Lymphoma, Myeloma & Leukemia, MS# CLML-D-14-00317R1

Solomon SR, SanacoreM, Zhang X, Brown, S, Holland K, Morris, LE, Bashey A. Calcineurin Inhibitor (DNI)-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide (CY) and Brief-Course Sirolimus Following Reduced Intensity Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation (2014), doi: 10,1016/j.bbmt.2014.07.020.

Bashey, A, Solomon, S. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplantation, advance online publication, 19 May 2014; doi:10.1038/bmt.2014.62.

Solomon SR, CA Sizemore, Z Zhang, S Brown, HK Holland, Le Morris, and A Bashey. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial. Bone Marrow Transplantation (2014) 49, 616-621; doi;10.1038/bmt.2014.2

NSH-BMT/Leukemia Programs are national leaders in developing and participating in cutting edge blood, marrow and leukemia clinical research trials. Please review Publications.

Join the Fight Against Cancer

By donating platelets and blood you can join the fight and directly impact the healthcare of patients being treated at NSH-BMT/Leukemia by donating with Atlanta Blood Services. To donate or find out additional information please go to Or Click here to Like ABS on Facebook:

A Celebration of Life: NSH-BMT Hosts Survivor Reunion at The Fernbank Museum

On October 19, 2013, approximately five hundred guests, which included over 150 patients, their caregivers and the NSH-BMT Program staff came to the Fernbank Museum to celebrate their survivorship and life. Guests were inspired by the key note address given by our patient Alyssa Phillips. Alyssa spoke about her journey from being a patient to a survivor. Patients were recognized for their years into survivorship, including the very first patient transplanted at NSH-BMT over 15 years ago. Ray Stovall and Martha Stovall, Stovall Hope Foundation, were honored with an award recognizing their years of service to NSH-BMT patients and families. The Stovall Hope Foundation allows patients and their caregivers to stay in comfortable, spacious and cost-free living quarters while undergoing transplant services at NSH-BMT.

Our special thanks to Dr. Gerry Connaghan, who travelled from Dublin Ireland to attend this special event. Dr. Connaghan was a founding physician of The Blood and Marrow Transplant Group of Georgia.

National Marrow Donor Program (NMDP): Post Transplant Mobile App is Now Available

To help physicians with the reference materials they need to care for transplant patients, the NMDP has developed an app with leading transplant organizations to help increase survival rates. For more information, please go to Post BMT Discharge Instructions. nmdpapp


The Blood and Marrow Transplant Program at Northside Hospital (NSH-BMT) provides the best of both worlds — clinical excellence and compassionate care. Committed to being the premier program in the Southeast, we provide outstanding state-of-the-art care for patients with leukemia and for those patients undergoing blood marrow and stem cell transplantation.